FREE Equity Delivery and MF
Flat ₹20/trade Intra-day/F&O
|
Dilip Davda recommend to "Avoid" the IPO.
Review By | Apply | May Apply | Neutral | Avoid | Not Rated |
---|---|---|---|---|---|
Count | 0 | 0 | 0 | 1 | 0 |
% | 0.00 | 0.00 | 0.00 | 100.00 | 0.00 |
Reviewer | Recommendation | Past Reviews |
---|---|---|
Dilip Davda | Avoid |
[Dilip Davda] The company is operating in a highly competitive and fragmented segment of agrochemicals. It has posted inconsistency in its bottom lines for the reported periods. There is some garble in the offer documents on financial data. Based on FY24 annualized super earnings, the issue appears aggressively priced discounting all near term positives. There is no harm in skipping this “High Risk/Low Return” bet. Read detail review...
Ambey Laboratories Limited peer comparison with similar listed entities. (As on March 31, 2023)
Company Name | EPS (Basic) | EPS (Diluted) | NAV (per share) (Rs) | P/E (x) | RoNW (%) | P/BV Ratio | Financial statements |
---|---|---|---|---|---|---|---|
Ambey Laboratories Limited | 2.57 | 2.57 | 13.32 | 19.33 | |||
Atul Ltd | 187.05 | 187.05 | 1,555.42 | 46.90 | 12.03 | 4.18 | Standalone |
Meghmani Organics Ltd. | 9.85 | 9.85 | 65.11 | 63.21 | 15.11 | 1.33 | Standalone |
Notes:
Ambey Laboratories IPO Reviews, analysis and views by popular members. Read Ambey Laboratories Limited IPO reviews by retail investors to find recommended ipo to buy.
Post Recommendation Manage Your IPO Reviews
Review By | Apply | May Apply | Neutral | Avoid |
---|---|---|---|---|
Count | 0 | 0 | 0 | 0 |
% |
Member | Review |
---|---|
No recommendation found. Be the first to post the
recommendation. |
Post Recommendation Manage Recommendations
Note:
FREE Intraday Trading (Eq, F&O)
Flat ₹20 Per Trade in F&O
|